This review found that chromium lowered fasting blood sugar but did not affect glycated haemoglobin, lipids and body mass index in patients with type 2 diabetes. These conclusions appear to be reliable.
Authors' objectives
To assess the effect of chromium versus placebo on the glucose and lipid profiles of patients with type 2 diabetes mellitus.
Searching
PubMed, SCOPUS, Scirus, and IranMedex were searched from 2000 to 2012. Search terms were reported. Google Scholar was also searched
Study selection
To be eligible for inclusion, studies had to be randomised controlled trials (RCTs) of chromium intake (≥250μg) for at least three months) among patients with type 2 diabetes mellitus. Primary outcomes were glycated haemoglobin (HbA1c) and fasting blood sugar. Secondary outcomes were total cholesterol, high-density lipoprotein cholesterol, lowdensity lipoprotein cholesterol, very low-density lipoprotein cholesterol, triglyceride and body mass index.
In included trials, approximately half of the participants were men. Dose of chromium ranged from 400μg to 1000μg per day. Treatment duration was either three months or six months.
Two reviewers independently screened studies for inclusion in the review.
Assessment of study quality
The Jadad scale (based on randomisation, blinding and withdrawals) was used to assess trial quality. Points were awarded from 0 to 5, with trials scoring 2 or less deemed to be of low quality, and those scoring at least 3 to be high quality. Low quality trials were excluded from the review.
The authors did not state how many reviewers were involved in the assessment of study quality for the review.
Data extraction
Data were extracted to present effect sizes and 95% confidence intervals.
The authors did not state how data were extracted for the review.
Methods of synthesis
Effect sizes were pooled in a series of meta-analyses and 95% confidence intervals were presented for the relevant outcomes. Heterogeneity was assessed using the Q statistic. Where heterogeneity was observed, a random-effects model was used.
A funnel plot, together with Egger's test and Begg-Mazumdar Kendall's test, were used to indicate the presence of publication bias.
Results of the review
Seven RCTs were included in the review (387 patients, range 20 to 137). Four trials scored the maximum 5 points on the quality scale; one trial scored 4.
The effect of chromium on glycated haemoglobin in patients with diabetes was not statistically significant compared with placebo (-0.33, 95% CI -0.72 to 0.06; seven RCTs). There was statistically significant heterogeneity, but no
